# Dipath

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dipath

- Industry: Software
- Headquarters: Hangzhou, China
- Website: www.dipath.cn
- Total disclosed funding: $18M
- Latest round: Series C (Jul 28, 2026)
- Investors on record: 10

## About

Based in Hangzhou, China, and founded in 2017, Hangzhou Dipath Technology Co., Ltd., doing business as Dipath or Deep Informatics, is a medical software development company. The company develops AI-assisted diagnostic tools with multiple modules through self-developed AI algorithms. It became a permanent director of the Beijing Tumor Pathology Precision Diagnosis Research Society in 2017, obtained the registration certificate of hardware and software Class II medical devices and was approved as a high-tech enterprise in Hangzhou in 2019. In 2020, the company became an AstraZeneca partner. In July 2026, the firm closed a series C funding round.

The company works with medical institutions and pharmaceutical companies to provide end-to-end digital pathology platforms, including intelligent slide scanners, the DeepPathAI model, and pathology information management systems. Core capabilities include multi-cancer intelligent diagnosis, remote consultation, slide scanning, cytology screening, and biomarker discovery for drug development.

The company generates revenue from the provision of digital pathology software, AI-assisted diagnostic solutions, pathology information management systems, medical imaging technologies, and related services for medical institutions and pharmaceutical companies.

The company plans to use the series C funding to continuously evolve its pathology large models, upgrade its multi-omics analysis platform, and expand its global market presence.

## Funding rounds

- Series C, Jul 28, 2026 — Zhejiang Yuhang Industrial Transformation & Upgrading Investment, Beida Fund, Fuzhe Capital, Fong Capital Partners
- Series B, Dec 4, 2020, $15M — Shenzhen Capital Real Estate Fund
- Series B, Jun 1, 2020 — Legend Capital, China International Capital Corporation, Jiangmen Capital
- Series A, Jul 3, 2018 — Legend Capital, IDG Capital, Jiangmen Capital, Jun He Capital
- Series A, Apr 16, 2018 — IDG Capital, Jiangmen Capital
- Angel, Jun 26, 2017, $2.2M — Jiangmen Capital

## Investors

- Jiangmen Capital (https://capitalatlas.ai/funds/jiangmen-capital) — Angel, Series A, Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- Legend Capital — Series A, Series B
- Jun He Capital — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B
- Zhejiang Yuhang Industrial Transformation & Upgrading Investment — Series C
- Beida Fund (https://capitalatlas.ai/funds/beida-fund) — Series C
- Fuzhe Capital (https://capitalatlas.ai/funds/fuzhe-capital) — Series C
- Fong Capital Partners (https://capitalatlas.ai/funds/fong-capital-partners) — Series C